From basic apoptosis discoveries to advanced selective BCL-2 family inhibitorsAvi Ashkenazi(Genentech), Wayne J. Fairbrother(Genentech), Joel D. Leverson(AbbVie (United States)), Andrew J. Souers(AbbVie (United States))Nature Reviews Drug DiscoveryFebruary 17, 201710.1038/nrd.2016.253Cited by 899SaveCiteExport RISWatch citationsAbstractRelated PapersCell DeathNika N. Danial, Stanley J. Korsmeyer|Cell|2004|4.6kDiscovering High-Affinity Ligands for Proteins: SAR by NMRSuzanne B. Shuker, Philip J. Hajduk, Robert Meadows et al.|Science|1996|2kbcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferationTimothy J. McDonnell, Natasha G. Deane, Frances M. Platt et al.|Cell|1989|1.2kSensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7Ingrid E. Wertz, Saritha Kusam, Cynthia Lam et al.|Nature|2011|810Bcl-2 family proteins are essential for platelet survivalH Zhang, Paul Nimmer, Stephen K Tahir et al.|Cell Death and Differentiation|2007|424